.Nature Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a mean consequence of 11 months, individuals along with metastatic stomach tumors that obtained biomarker-matched therapies based upon distributing cyst DNA profiling showed a better medical benefit than those receiving unparalleled therapy.